CDK4-6 inhibitors in breast cancer: current status and future development

References

• Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res. 1996;68:67–108. PubMed PMID: 8712071; eng.
   PubMed Web of Science ®Google Scholar
• Fornier MN, Rathkopf D, Shah M, et al. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res. 2007;13(19):5841–5846.
   PubMed Web of Science ®Google Scholar
• Tan AR, Yang X, Berman A, et al. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2004 Aug 1;10(15):5038–5047. PubMed PMID: 15297405; eng.
   PubMed Web of Science ®Google Scholar
• Sedlacek H, Czech J, Naik R, et al. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int J Oncol. 1996 Dec;9(6):1143–1168. PubMed PMID: 21541623; eng.
   PubMed Web of Science ®Google Scholar
• Bose P, Simmons GL, Grant S. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Investig Drugs. 2013 Jun;22(6):723–738. PubMed PMID: 23647051; PubMed Central PMCID: PMCPMC4039040. eng.
   PubMed Web of Science ®Google Scholar
• Sausville EA, Arbuck SG, Messmann R, et al. Phase I Trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol. 2001;19(8):2319–2333. PubMed PMID: 11304786.
   PubMed Web of Science ®Google Scholar
• Kalra S, Joshi G, Munshi A, et al. Structural insights of cyclin dependent kinases: implications in design of selective inhibitors. Eur J Med Chem. 2017 Dec 15;142:424–458. PubMed PMID: 28911822; eng.
   PubMed Web of Science ®Google Scholar
• Toogood PL, Harvey PJ, Repine JT, et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem. 2005 Apr 7;48(7):2388–2406. PubMed PMID: 15801831; eng.
   PubMed Web of Science ®Google Scholar
• Baughn LB, Di Liberto M, Wu K, et al. A novel orally active small molecule potently induces g1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res. 2006;66(15):7661–7667.
   PubMed Web of Science ®Google Scholar
• Marzec M, Kasprzycka M, Lai R, et al. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood. 2006;108(5):1744–1750.
   PubMed Web of Science ®Google Scholar
• Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Research: BCR. 2009;11(5):R77. PubMed PMID: 19874578; PubMed Central PMCID: PMCPMC2790859. eng.
   PubMed Web of Science ®Google Scholar
• Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3(11):1427–1438.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Lorusso PM, Demichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2012 Jan 15;18(2):568–576. PubMed PMID: 22090362; eng.
   PubMed Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016 Nov 17;375(20):1925–1936. PubMed PMID: 27959613; eng.
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–439.
   PubMed Web of Science ®Google Scholar
• Hu W, Sung T, Jessen BA, et al. Mechanistic investigation of bone marrow suppression associated with palbociclib and its differentiation from cytotoxic chemotherapies. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2016 Apr 15;22(8):2000–2008. PubMed PMID: 26631614; eng.
   PubMed Web of Science ®Google Scholar
• Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015 Jan;16(1):25–35. PubMed PMID: 25524798; eng.
   PubMed Web of Science ®Google Scholar
• FDA. Full prescribing information for palbociclib 2017 [cited 2018 Jul 11]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207103s004lbl.pdf
   Google Scholar
• DeMichele A, Clark AS, Tan KS, et al. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase ii activity, safety, and predictive biomarker assessment. Clin Cancer Res. 2015;21(5):995–1001.
   PubMed Web of Science ®Google Scholar
• Malorni L, Curigliano G, Minisini AM, et al. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: tREnd trial. Ann Oncology: Official Journal Eur Soc Med Oncol. 2018 Jun 11. PubMed PMID: 29893790; eng. DOI:10.1093/annonc/mdy214.
   Google Scholar
• Clifton K, Kimmel J, Yi M, et al. Abstract P3-11-03: the impact of dose delays and reductions on toxicity and progression free survival (PFS) in patients receiving palbociclib. Cancer Res. 2018;78(4Supplement):P3-11–03-P3-11–03.
   Google Scholar
• Li N, Du EX, Chu L, et al. Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2- metastatic breast cancer. Expert Opin Pharmacother. 2017 Aug;18(12):1167–1178. PubMed PMID: 28699804; eng.
   PubMed Web of Science ®Google Scholar
• Sun W, Klamerus KJ, Yuhas LM, et al. Impact of acid-reducing agents on the pharmacokinetics of palbociclib, a weak base with pH-dependent solubility, with different food intake conditions. Clin Phar Drug Dev. 2017 Nov;6(6):614–626. PubMed PMID: 28430398; eng.
   PubMed Web of Science ®Google Scholar
• Ruiz-Garcia A, Plotka A, O’Gorman M, et al. Effect of food on the bioavailability of palbociclib. Cancer Chemother Pharmacol. 2017 Mar;79(3):527–533. PubMed PMID: 28204912; eng.
   PubMed Web of Science ®Google Scholar
• Hoffman JT, Loi C-M, O’Gorman M, et al. Abstract LB-196: A phase I open-label, fixed-sequence, two-period crossover study of the effect of multiple doses of Itraconazole on Palbociclib (PD–0332991) pharmacokinetics in healthy volunteers. Cancer Res. 2016;76(14Supplement):LB–196.
   Google Scholar
• Hoffman JT, Plotka A, O’Gorman M, et al. Abstract 4515: A phase 1 randomized, open-label, fixed-sequence, 2-period study of the effect of multiple doses of rifampin on palbociclib (PD-0332991) pharmacokinetics in healthy volunteers. Cancer Res. 2015;75(15 Supplement):4515.
   Google Scholar
• Iwata H, Im SA, Masuda N, et al. PALOMA-3: phase III trial of fulvestrant with or without palbociclib in premenopausal and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer that progressed on prior endocrine therapy-safety and efficacy in asian patients. J Global Oncology. 2017 Aug;3(4):289–303. .
   PubMed Web of Science ®Google Scholar
• VanderWel SN, Harvey PJ, McNamara DJ, et al. Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4. J Med Chem. 2005 Apr 7;48(7):2371–2387. PubMed PMID: 15801830; eng.
   PubMed Web of Science ®Google Scholar
• Rader J, Russell MR, Hart LS, et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2013 Nov 15;19(22):6173–6182. PubMed PMID: 24045179; PubMed Central PMCID: PMCPMC3844928. eng.
   PubMed Web of Science ®Google Scholar
• Zhang YX, Sicinska E, Czaplinski JT, et al. Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo. Mol Cancer Ther. 2014 Sep;13(9):2184–2193. PubMed PMID: 25028469; eng.
   PubMed Web of Science ®Google Scholar
• Kim S, Loo A, Chopra R, et al. Abstract PR02: LEE011: an orally bioavailable, selective small molecule inhibitor of CDK4/6– reactivating Rb in cancer. Mol Cancer Ther. 2013;12(11Supplement):PR02.
   Google Scholar
• O’Brien NA, Tomaso ED, Ayala R, et al. Abstract 4756: in vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer. Cancer Res. 2014;74(19 Supplement):4756.
   Web of Science ®Google Scholar
• Infante JR, Cassier PA, Gerecitano JF, et al. A Phase I study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2016 Dec 1;22(23):5696–5705. PubMed PMID: 27542767; PubMed Central PMCID: PMCPMC5621377. eng.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016 Nov 3;375(18):1738–1748. PubMed PMID: 27717303; eng.
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy J, Petrakova K, Sonke GS, et al. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat. 2018;168(1):127–134. PubMed PMID: PMC5847028.
   PubMed Web of Science ®Google Scholar
• Conte P, Paluch-Shimon S, Burris HA, et al. First-line ribociclib + letrozole in patients with HR+, HER2–advanced breast cancer (ABC) who received prior (neo)adjuvant therapy: a subgroup analysis of the MONALEESA-2 trial. The Breast. 2017;32:S70.
   Web of Science ®Google Scholar
• Sonke GS, Hart LL, Campone M, et al. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat. 2018;167(3):659–669. PubMed PMID: PMC5807486.
   PubMed Web of Science ®Google Scholar
• Yap YS, Tseng LM, Blackwell KL, et al. LBA1 First-line ribociclib + letrozole in postmenopausal Asian women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): A subgroup analysis from MONALEESA-2. Ann Oncol. 2016;27(suppl_9):mdw637.001.
   PubMedGoogle Scholar
• FDA. Full prescribing information for ribociclib 2017 [cited 2018 Jul 11]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209092s000lbl.pdf
   Google Scholar
• Tripathy D, Im S-A, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018. DOI:10.1016/S1470-2045(18)30292-4.
   Web of Science ®Google Scholar
• Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2018 Jun 3:Jco2018789909. PubMed PMID: 29860922; eng. DOI: 10.1200/jco.2018.78.9909
   Google Scholar
• Abdelhady AM, Samant T, Chakraborty A, et al. Abstract P1-14-05: ribociclib dose recommendations for potential pharmacokinetic drug interaction and in special patient populations with organ impairment. Cancer Research. 2018;78(4 Supplement):P1-14-05.
   Google Scholar
• Dhuria SV, Siddani R, Kosecki CM, et al. A phase I food-effect study of the ribociclib (LEE011) drug-in-capsule (DiC) formulation in healthy subjects. J Clin Oncol. 2015;33(15_suppl):e13577.
   Web of Science ®Google Scholar
• Yap Y, Ito Y, Suarez-Vizcarra J, et al. Abstract P5-21-28: phase Ib study of ribociclib + letrozole in Asian non-Japanese patients with hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESASIA. Cancer Res. 2018;78(4Supplement):P5-21–28.
   Google Scholar
• Gelbert LM, Cai S, Lin X, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014 Oct;32(5):825–837. PubMed PMID: 24919854; PubMed Central PMCID: PMCPMC4169866. eng.
   PubMed Web of Science ®Google Scholar
• Chen P, Lee NV, Hu W, et al. Spectrum and degree of CDK drug interactions predicts clinical performance. Mol Cancer Ther. 2016 Oct;15(10):2273–2281. PubMed PMID: 27496135; eng.
   PubMed Web of Science ®Google Scholar
• Tate SC, Cai S, Ajamie RT, et al. Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2014 Jul 15;20(14):3763–3774. PubMed PMID: 24850847; eng.
   PubMed Web of Science ®Google Scholar
• Patnaik A, Rosen LS, Tolaney SM, et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov. 2016 Jul;6(7):740–753. PubMed PMID: 27217383; eng.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2017 Nov 10;35(32):3638–3646. PubMed PMID: 28968163; eng.
   PubMed Web of Science ®Google Scholar
• Sledge GW Jr., Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clinical Oncology. 2017 Sep 1;35(25):2875–2884. PubMed PMID: 28580882; eng.
   PubMed Web of Science ®Google Scholar
• Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, A Phase II study of abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR(+)/HER2(-) metastatic breast cancer. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2017 Sep 1;23(17):5218–5224. 10.1158/1078-0432.Ccr-17-0754. PubMed PMID: 28533223; PubMed Central PMCID: PMCPMC5581697. eng.
   PubMed Web of Science ®Google Scholar
• FDA. Full prescribing information for abemaciclib 2018 [cited 2018 Jul 11]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208855s000lbl.pdf
   Google Scholar
• Tolaney S, Lam A, Mukundan S, et al. Abstract P6-15-01: analysis of renal function in MONARCH 1: A phase 2 study of abemaciclib, a CDK4 & 6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for metastatic breast cancer (MBC). Cancer Res. 2017;77(4Supplement):P6-15–01.
   Google Scholar
• Kulanthaivel P, Mahadevan D, Turner PK, et al. Abstract CT153: pharmacokinetic drug interactions between abemaciclib and CYP3A inducers and inhibitors. Cancer Res. 2016;76(14Supplement):CT153.
   Google Scholar
• Turner K, Chappell J, Kulanthaivel P, et al. Abstract CT152: food effect on the pharmacokinetics of 200-mg abemaciclib in healthy subject. Cancer Res. 2016;76(14Supplement):CT152.
   Google Scholar
• Finn RS, Crown J, Lang I, et al. Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18). J Clin Oncol. 2017;35(15_suppl):1001.
   Google Scholar
• Businesswire. Pfizer announces overall survival results from phase 3 PALOMA-3 Trial of IBRANCE® (Palbociclib) in HR+, HER2- metastatic breast cancer 2018 [cited 2018 Jul 11]. Available from: https://www.businesswire.com/news/home/20180625005290/en/
   Google Scholar
• Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor–positive advanced breast cancer. New England J Med. 2015;373(3):209–219. PubMed PMID: 26030518.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncology: Official Journal Eur Soc Med Oncol. 2018 Apr 27 PubMed PMID: 29718092; eng. DOI:10.1093/annonc/mdy155.
   Google Scholar
• Gao JJ, Cheng J, Bloomquist E, et al. Benefit of CDK 4/6 inhibition in less common breast cancer subsets: A U.S. Food and drug administration pooled analysis. J Clin Oncol. 2018;36(15_suppl):1024.
   Web of Science ®Google Scholar
• Dean JL, McClendon AK, Hickey TE, et al. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle (Georgetown, Tex). 2012 Jul 15;11(14):2756–2761. PubMed PMID: 22767154; PubMed Central PMCID: PMCPMC3409015. eng.
   PubMed Web of Science ®Google Scholar
• Gong X, Litchfield LM, Webster Y, et al. Genomic aberrations that activate d-type cyclins are associated with enhanced sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib. Cancer Cell. 2017 Dec 11;32(6):761–776.e6. PubMed PMID: 29232554; eng.
   PubMed Web of Science ®Google Scholar
• Vijayaraghavan S, Karakas C, Doostan I, et al. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat Commun. 2017 Jun 27;8:15916. PubMed PMID: 28653662; PubMed Central PMCID: PMCPMC5490269. eng.
   PubMed Web of Science ®Google Scholar
• Xu H, Yu S, Liu Q, et al. Recent advances of highly selective CDK4/6 inhibitors in breast cancer. J Hematol Oncol. 2017 Apr 24;10(1):97. PubMed PMID: 28438180; PubMed Central PMCID: PMCPMC5404666. eng.
   PubMedGoogle Scholar
• Turner NC, O’Leary B, Cutts R, et al. Genetic landscape of resistance to CDK4/6 inhibition in circulating tumor DNA (ctDNA) analysis of the PALOMA3 trial of palbociclib and fulvestrant versus placebo and fulvestrant. J Clin Oncol. 2018;36(15_suppl):1001.
   Web of Science ®Google Scholar
• Herrera-Abreu MT, Palafox M, Asghar U, et al. Early adaptation and acquired resistance to cdk4/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res. 2016 Apr 15;76(8):2301–2313. PubMed PMID: 27020857; PubMed Central PMCID: PMCPMC5426059. eng.
   PubMed Web of Science ®Google Scholar
• Vora SR, Juric D, Kim N, et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell. 2014 Jul 14;26(1):136–149. PubMed PMID: 25002028; PubMed Central PMCID: PMCPMC4155598. eng.
   PubMed Web of Science ®Google Scholar
• de Leeuw R, McNair C, Schiewer MJ, et al. MAPK reliance via acquired CDK4/6 inhibitor resistance in cancer. Clin Cancer Res. 2018. DOI:10.1158/1078-0432.Ccr-18-0410.
   PubMed Web of Science ®Google Scholar
• Sullivan RJ, Amaria RN, Lawrence DP, et al. Abstract PR06: phase 1b dose-escalation study of trametinib (MEKi) plus palbociclib (CDK4/6i) in patients with advanced solid tumors. Mol Cancer Ther. 2015;14(12Supplement 2):PR06 .
   Google Scholar
• Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumor immunity. Nature. 2017 Aug 16;548(7668):471–475. PubMed PMID: PMC5570667.
   PubMed Web of Science ®Google Scholar
• Tolaney SM, Kabos P, Dickler MN, et al. Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab. J Clin Oncol. 2018;36(15_suppl):1059.
   Web of Science ®Google Scholar
• Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997–3005.
   PubMed Web of Science ®Google Scholar
• Kaufman PA, Toi M, Neven P, et al. Health-related quality of life (HRQoL) in MONARCH 2: abemaciclib plus fulvestrant in women with HR+, HER2- advanced breast cancer (ABC) who progressed on endocrine therapy. J Clin Oncol. 2018;36(15_suppl):1049.
   PubMed Web of Science ®Google Scholar
• Harbeck N, Iyer S, Turner N, et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncology: Official Journal Eur Soc Med Oncol. 2016 Jun;27(6):1047–1054. PubMed PMID: 27029704; PubMed Central PMCID: PMCPMC4880065. eng.
   PubMed Web of Science ®Google Scholar
• Verma S, O’Shaughnessy J, Burris HA, et al. Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: results from MONALEESA-2. J Clin Oncol. 2017;35(15_suppl):1020.
   Google Scholar
• Verma S, Bartlett CH, Schnell P, et al. Palbociclib in combination with fulvestrant in women with hormone receptor-positive/HER2-negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III Study (PALOMA-3). Oncologist. 2016 Oct;21(10):1165–1175. PubMed PMID: 27368881; PubMed Central PMCID: PMCPMC5061543. eng.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Sledge GW, Johnston SRD, et al. The association of early toxicity and outcomes for patients treated with abemaciclib. J Clin Oncol. 2018 May 20;36(15_suppl):1053.
   Web of Science ®Google Scholar
• Bekaii-Saab TS, Ou F-S, Anderson DM, et al. Regorafenib dose optimization study (ReDOS): randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC)–An ACCRU Network study. J Clin Oncol. 2018;36(4_suppl):611.
   Web of Science ®Google Scholar
• Finn R, Jiang Y, Rugo H, et al. Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER +/HER2– advanced breast cancer (ABC). Ann Oncol. 2016;27(suppl_6):LBA15.
   Google Scholar
• Wang L, Wang J, Blaser BW, et al. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood. 2007;110(6):2075–2083.
   PubMed Web of Science ®Google Scholar